Search

Your search keyword '"Vollmar, J."' showing total 892 results
Start Over Author "Vollmar, J."
892 results on '"Vollmar, J."'

4. Efficacy and safety of direct-acting antiviral therapy in previous hard-to-treat patients with recurrent hepatitis C virus infection after liver transplantation: a real-world cohort

Author

Bernuth S, Grimm D, Vollmar J, Darstein F, Mittler J, Heise M, Hoppe-Lotichius M, Galle PR, Lang H, and Zimmermann T

Subjects
HCV, hepatitis C, DAA, direct acting antivirals, liver transplantation, sofosbuvir, Therapeutics. Pharmacology, RM1-950
Abstract

Sebastian Bernuth,1 Daniel Grimm,1 Johanna Vollmar,1 Felix Darstein,1 Jens Mittler,2 Michael Heise,2 Maria Hoppe-Lotichius,2 Peter R Galle,1 Hauke Lang,2 Tim Zimmermann1 1First Department of Internal Medicine, Transplant Hepatology, 2General-, Abdominal- and Transplant- Surgery, University Medical Center, Johannes Gutenberg University, Mainz, Germany Background: Recurrent hepatitis C virus (HCV) infection after liver transplantation (LT) has been a frequent and relevant problem in the past two decades. This analysis evaluated the efficacy and safety of new interferon (IFN)-free direct-acting antiviral (DAA) therapies in a large real-world cohort of HCV patients after LT.Methods: We retrospectively analyzed a cohort of 157 patients infected with HCV who underwent deceased donor LT between 1997 and 2014. Patient survival, outcome, and side effects of antiviral therapy were assessed.Results: Survival with recurrent HCV genotype 1 (GT1) infection was inferior to other HCV GTs (P=0.01). The overall sustained virological response (SVR) rate with new DAA therapy was 94.6% (n=37). Patients with both GT1 and other GTs reached SVR rates >90%. We noticed a few side effects, mainly caused by ribavirin, and only one discontinuation in DAA-treated patients.Conclusion: DAA therapy was effective and safe in previous hard-to-treat patients after LT in this real-world cohort. Keywords: HCV, DAA, liver transplantation, reinfection, sustained virological response, SVR

Published
2017

5. Factors influencing the presence of potentially explosive gases during colonoscopy: Results of the SATISFACTION study

Author

Carnovali, M., Spada, Cristiano, Uebel, P., Bocus, P., Cannizzaro, Rino, Cavallaro, Fabio, Cesana, Bruno Mario, Cesaro, Paola, Costamagna, Guido, Dipaolo, D., Ferrari, A. P., Hinkel, C., Kashin, S., Massella, A., Melnikova, E., Orsatti, A., Ponchon, T., Prada, A., Radaelli, F., Sferrazza, Silvia, Soru, P., Testoni, P. A., Tontini, G. E., Vecchi, M., Fiori, G., Adyshirin, Z. S., Amato, Arianna, Anesi, A., Arpurt, J. P., Attardo, S., Balzarini, M., Bellon, S., Benini, M., Blanc, P., Bonato, G., Bordin, D., Bravi, I., Bulanova, N., Bunkova, E., Cadoni, S., Carparelli, S., Chashkova, E. Y., Ciprandi, Guido, Ciuffini, Cristina, Codazzi, M., Elli, L., Fedorishina, O., Hartmann, D., Jakobs, R., Janke, D., Kamalova, O., Karpova, I., Khitaryan, A., Lombardo, V., Lovera, Mauro, Maiero, S., Manes, G., Martino, G., Merkulova, E., Mura, D., Mutignani, Massimiliano, Occhipinti, P., Pescarolo, M., Petruzziello, Lucio, Pioche, M., Pisani, Anna, Poltorykhina, E., Pretti, C., Puzzono, M., Realdon, S., Reiche, P., Roberto, P., Roman, K., Rondonotti, E., Schettino, M., Segato, S., Shishin, K., Spina, L., Stefania, M., Trovato, C., Valats, J. C., Vena, N., Veselov, V., Viale, E., Vollmar, J., Zavyalov, D., Zimmermann, Thomas Alexander, Spada C. (ORCID:0000-0002-5692-0960), Cannizzaro R., Cavallaro F., Cesana B. M., Cesaro P., Costamagna G. (ORCID:0000-0002-8100-2731), Sferrazza S., Amato A., Ciprandi G., Ciuffini C., Lovera M., Mutignani M. (ORCID:0000-0002-1272-4888), Petruzziello L., Pisani A., Zimmermann T., Carnovali, M., Spada, Cristiano, Uebel, P., Bocus, P., Cannizzaro, Rino, Cavallaro, Fabio, Cesana, Bruno Mario, Cesaro, Paola, Costamagna, Guido, Dipaolo, D., Ferrari, A. P., Hinkel, C., Kashin, S., Massella, A., Melnikova, E., Orsatti, A., Ponchon, T., Prada, A., Radaelli, F., Sferrazza, Silvia, Soru, P., Testoni, P. A., Tontini, G. E., Vecchi, M., Fiori, G., Adyshirin, Z. S., Amato, Arianna, Anesi, A., Arpurt, J. P., Attardo, S., Balzarini, M., Bellon, S., Benini, M., Blanc, P., Bonato, G., Bordin, D., Bravi, I., Bulanova, N., Bunkova, E., Cadoni, S., Carparelli, S., Chashkova, E. Y., Ciprandi, Guido, Ciuffini, Cristina, Codazzi, M., Elli, L., Fedorishina, O., Hartmann, D., Jakobs, R., Janke, D., Kamalova, O., Karpova, I., Khitaryan, A., Lombardo, V., Lovera, Mauro, Maiero, S., Manes, G., Martino, G., Merkulova, E., Mura, D., Mutignani, Massimiliano, Occhipinti, P., Pescarolo, M., Petruzziello, Lucio, Pioche, M., Pisani, Anna, Poltorykhina, E., Pretti, C., Puzzono, M., Realdon, S., Reiche, P., Roberto, P., Roman, K., Rondonotti, E., Schettino, M., Segato, S., Shishin, K., Spina, L., Stefania, M., Trovato, C., Valats, J. C., Vena, N., Veselov, V., Viale, E., Vollmar, J., Zavyalov, D., Zimmermann, Thomas Alexander, Spada C. (ORCID:0000-0002-5692-0960), Cannizzaro R., Cavallaro F., Cesana B. M., Cesaro P., Costamagna G. (ORCID:0000-0002-8100-2731), Sferrazza S., Amato A., Ciprandi G., Ciuffini C., Lovera M., Mutignani M. (ORCID:0000-0002-1272-4888), Petruzziello L., Pisani A., and Zimmermann T.

Abstract

This study tested the hypothesis that bowel preparation with mannitol should not affect the colonic concentration of H2 and CH4. Therefore, the SATISFACTION study, an international, multicenter, randomized, parallel-group phase II–III study investigated this issue. The phase II dose-finding part of the study evaluated H2, CH4, and O2 concentrations in 179 patients randomized to treatment with 50 g, 100 g, or 150 g mannitol. Phase III of the study compared the presence of intestinal gases in 680 patients randomized (1:1) to receive mannitol 100 g in single dose or a standard split-dose 2 L polyethylene glycol (PEG)-Asc preparation (2 L PEG-Asc). Phase II results showed that mannitol did not influence the concentration of intestinal gases. During phase III, no patient in either group had H2 or CH4 concentrations above the critical thresholds. In patients with H2 and/or CH4 levels above detectable concentrations, the mean values were below the risk thresholds by at least one order of magnitude. The results also highlighted the effectiveness of standard washing and insufflation maneuvers in removing residual intestinal gases. In conclusion, bowel cleansing with mannitol was safe as the concentrations of H2 and CH4 were the same as those found in patients prepared with 2 L PEG-Asc. In both groups, the concentrations of gases were influenced more by the degree of cleansing achieved and the insufflation and washing maneuvers performed than by the preparation used for bowel cleansing. The trial protocol was registered with ClinicalTrials.gov (https://clinicaltrials.gov/ct2/show/NCT04759885) and with EudraCT (eudract_number: 2019-002856-18).

Published
2023

8. Efficacy and safety of a conversion from the original tacrolimus and mycophenolate mofetil to the generics Tacpan® and Mowel® after liver transplantation

Author

Vollmar J, Bellmann MC, Darstein F, Hoppe-Lotichius M, Mittler J, Heise M, Rüttger B, Weyer V, Zimmermann A, Lang H, Galle PR, and Zimmermann T

Subjects
Therapeutics. Pharmacology, RM1-950
Abstract

Johanna Vollmar,1 Maren Christina Bellmann,1 Felix Darstein,1 Maria Hoppe-Lotichius,2 Jens Mittler,2 Michael Heise,2 Bernd Rüttger,3 Veronika Weyer,4 Anca Zimmermann,5 Hauke Lang,2 Peter R Galle,1 Tim Zimmermann1 1First Department of Internal Medicine, Gastroenterology and Hepatology, Johannes Gutenberg University, Mainz, Germany; 2Department of Hepatobiliary and Transplantation Surgery, Johannes Gutenberg University, Mainz, Germany; 3Panacea Biotec Germany GmbH, Munich, Germany; 4Institute for Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center, Johannes Gutenberg University, Mainz, Germany; 5First Department of Internal Medicine, Endocrinology and Metabolic Diseases, Johannes Gutenberg University, Mainz, Germany Background: Expensive pharmaceuticals are a major reason for cost intensive health care systems. Long-term immunosuppressive therapy plays a relevant role after organ transplantation. Patents of original drugs have expired and cheaper products are available. Little data are available regarding efficacy and safety of generic immunosuppressive agents.Methods: In this prospective study, 25 patients, who were clinically stable for a minimum of 2 years after liver transplantation, were converted from the original formulations of tacrolimus (TAC) and mycophenolate mofetil to the generics Tacpan® (TAP) and Mowel® (MOW). Patients were followed-up for 6 months. Results were compared retrospectively to 25 age- and sex-matched controls treated with the original brands.Results: In the matched-pair analysis of TAC trough level/dose ratio, no significant difference was found between TAP/MOW and TAC/mycophenolate mofetil groups. No acute rejection occurred in either group. In total, 17 patients reported mild side effects in the TAP/MOW group. The most common side effects were gastrointestinal symptoms. Intra-individual analysis of costs revealed a considerable cost reduction in the TAP/MOW group (in median 25.03%; P

Published
2015

9. Pharmacokinetics of oral mannitol for bowel preparation for colonoscopy

Author

Fiori, G., Spada, Cristiano, Soru, P., Tontini, G. E., Bravi, I., Cesana, Bruno Mario, Cesaro, Paola, Manes, G., Orsatti, A., Prada, A., Quadarella, Alessandro, Schettino, M., Spina, L., Trovato, C., Carnovali, M., Vecchi, M., Cavallaro, Fabio, Codazzi, M., De Nucci, G., De Roberto, G., Devani, M., Di Paolo, D., Elli, L., Hinkel, C., Jakobs, R., Janke, D., Lombardo, V., Lovera, Mauro, Radaelli, F., Ravizza, D., Uebel, P., Valats, J. C., Vollmar, J., Zimmermann, Thomas Alexander, Ciprandi, Guido, Spada C. (ORCID:0000-0002-5692-0960), Cesana B. M., Cesaro P., Quadarella A., Cavallaro F., Lovera M., Zimmermann T., Ciprandi G., Fiori, G., Spada, Cristiano, Soru, P., Tontini, G. E., Bravi, I., Cesana, Bruno Mario, Cesaro, Paola, Manes, G., Orsatti, A., Prada, A., Quadarella, Alessandro, Schettino, M., Spina, L., Trovato, C., Carnovali, M., Vecchi, M., Cavallaro, Fabio, Codazzi, M., De Nucci, G., De Roberto, G., Devani, M., Di Paolo, D., Elli, L., Hinkel, C., Jakobs, R., Janke, D., Lombardo, V., Lovera, Mauro, Radaelli, F., Ravizza, D., Uebel, P., Valats, J. C., Vollmar, J., Zimmermann, Thomas Alexander, Ciprandi, Guido, Spada C. (ORCID:0000-0002-5692-0960), Cesana B. M., Cesaro P., Quadarella A., Cavallaro F., Lovera M., Zimmermann T., and Ciprandi G.

Abstract

This study aimed to define the pharmacokinetics (PKs) of oral mannitol used as an osmotic laxative for bowel preparation for colonoscopy. The PKs of oral mannitol was evaluated in a substudy as part of a phase II dose-finding, international, multicenter, randomized, parallel-group, endoscopist-blinded study. Patients were randomly assigned to take 50, 100, or 150 g mannitol. Venous blood samples were drawn at baseline (T0), 1 h (T1), 2 h (T2), 4 h (T4), and 8 h (T8) after completion of mannitol self-administration. The mean mannitol plasma concentrations (mg/ml) were dose-dependent with a consistent difference among doses. The mean maximum concentration (Cmax) ± SD was 0.63 ± 0.15, 1.02 ± 0.28, and 1.36 ± 0.39 mg/ml, in the three dosage groups, respectively. The mean area under the curve from zero to infinity (AUC0−∞) was 2.667 ± 0.668, 4.992 ± 1.706, and 7.403 ± 3.472 mg/ml*h in the 50, 100, and 150 g mannitol dose groups, respectively. Bioavailability was similar in the three dose groups and was just over 20% (0.243 ± 0.073, 0.209 ± 0.081, and 0.228 ± 0.093 in the 50, 100, and 150 g mannitol dose groups, respectively). The present study showed that the bioavailability of oral mannitol is just over 20% and is similar for the three tested doses (50, 100, and 150 g). The linear increase in Cmax, AUC0−t8, and AUC0−∞ must be considered when choosing the oral mannitol dose for bowel preparation to avoid its systemic osmotic effects.

Published
2022

21. Survival of patients with unresectable cholangiocarcinoma undergoing palliative chemotherapy - real world data from a German tertiary care center

Author

Gairing, SJ, additional, Thol, F, additional, Czauderna, C, additional, Thomaidis, T, additional, Gamstätter, T, additional, Huber, Y, additional, Vollmar, J, additional, Lorenz, J, additional, Michel, M, additional, Bartsch, F, additional, Müller, L, additional, Kloeckner, R, additional, Galle, PR, additional, Wörns, M-A, additional, Marquardt, JU, additional, Möhler, M, additional, Weinmann, A, additional, and Foerster, F, additional

Published
2021
Full Text
View/download PDF

42. Gastroenterologie

Author

Müller-Lissner, S. A., Pace, F., Weiser, H. F., Siewert, J. R., Blum, A. L., Erckenbrecht, E., Berges, W., Erckenbrecht, J., Wienbeck, M., Sauerbruch, T., Wirsching, R., Leisner, B., Weinzierl, M., Pfahler, M., Paumgartner, G., Althoff, P.-H., Hellstern, A., Wöhrle, G., Classen, M., Hanrath, R.-D., Fritsch, W.-P., Scholten, T., Müller, J. E., Strohmeyer, G., Caspari, J., Domschke, S., Dembiński, A., Domschke, W., Dammann, H. G., Müller, P., Simon, B., Sonnenberg, A., West, C., Panzer, S., Meryn, S., Lochs, H., Nowotny, P., Herzog, P., Ebener, B., Holtermüller, K. H., Rösch, W., Schaudi, J., Elster, K., Lembcke, B., Fölsch, U. R., Caspary, W. F., Creutzfeldt, W., Körner, M. M., Heckers, H., Melcher, F. W., Schmahl, F. W., Buscher, H.-P., Sauerbier, H., Kramer, W., Kurz, G., Gerok, W., Stellaard, F., Brunhölzl, C., Hansen, W. E., Maurer, H., Haberland, H., Vollmar, J., Bräuning, C., Matern, S., Schill, A., Ritz, R., Lehnert, W., Matern, H., Raedsch, R., Stiehl, A., Czygan, P., Walker, S., Kommerell, B., Kutz, K., Leiss, O., Bergmann, K., Dlugosz, J., Singer, M. V., Eyßelein, V., Wentz, H., Goebell, H., Lohse, J., Krämer, R., Dörner, M., Wurster, K., Kaess, H., Niederau, C., Häger, V., Weiss, H., Sommer, W., Weiss, A., Rethel, R., Keller, W., Malchow, H., Ewe, K., Brandes, J. W., Ehms, H., Jesdinsky, H. J., Karbach, U., Schramm, P., Bossaller, C., Schober, O., Wellmann, W., Lehr, L., Schölmerich, J., Becher, M.-S., Köttgen, E., Hoppe-Seyler, P., Löhle, E., Vuilleumier, J. P., Peskar, B. M., Weiler, H., Kröner, E. E., Kruis, W., Holl, J., Paulus, W., Schüßler, P., and Schlegel, Bernhard, editor

Published
1982
Full Text
View/download PDF

43. Pathogenese, Prävention und Therapie der Arteriosklerose

Author

Hort, W., Greten, H., Schettler, G., Bollinger, A., Breddin, H. K., Lasch, H. G., Schöndorf, T. H., Grüntzig, A., Brüschke, R., Rodewald, G., Rödiger, W., Kalmar, P., Mathey, D., Voss, H., Vollmar, J. F., Bode, G., Klör, H. U., Stange, E., Ditschuneit, H., and Miehlke, K., editor

Published
1981
Full Text
View/download PDF

50. Venenfehlbildungen und extravasale Abflußhindernisse

Author

Vollmar, J., Allgöwer, M., editor, Bauer, K. H., editor, Block, W., editor, Brunner, A., editor, de la Camp, H. Bürkle, editor, Denk, W., editor, Derra, E., editor, Frey, E. K., editor, Linder, F., editor, v. Seemen, H., editor, and Zenker, R., editor

Published
1969
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results